References
- Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl 2007;67:5–14.
- Gürcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10–25.
- Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13:R7
- Gibbs S, Pout G, Wimperis J. Rapid infusion rituximab is as effective and safe as conventional infusion regimes in the treatment of diffuse large B cell lymphoma: a 2 year prospective study. Haematologica 2007;92(Suppl. 2): Abstract 0708.
- Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007;109:4171–4173.
- Genentech, Inc. Rituxan. South San Francisco, CA: Genentech, Inc; 2008. Available from: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf
- SPC Rituximab. Available from: http://www.medicines.org.uk/
- Pace E, Dennison S, Morris J, et al. Chemotherapy in the community: what do patients want? Eur J Cancer Care 2009;18:209–215.